The tweet was deleted by the author.
But we saved everything 🙂.
Allogene Therapeutics has published its corporate update for the second quarter of 2026, outlining recent business advances.
The update includes progress in its allogeneic CAR-T and cell therapy portfolio, reflecting continued efforts to innovate in the cell therapy field. Investors and stakeholders can access the full report through the company’s official channels.
View post on X Loading...
Earlier this year, Allogene Therapeutics gained FDA RMAT and Fast Track designations for its allogeneic CAR-T therapy cema-cel in LBCL, according to a previous report here. The company also launched a trial testing a new first-line consolidation method to assess relapse risk in LBCL patients here. Both initiatives marked key steps in advancing its cell therapy pipeline.